Adma Biologics (ADMA) Receivables (2012 - 2025)

Adma Biologics' Receivables history runs 14 years deep, the most recent figure standing at $158.4 million for Q4 2025.

• Quarterly Receivables rose 216.86% year-over-year to $158.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $158.4 million (up 216.86% YoY) and the FY2025 annual result came in at $158.4 million, up 216.86% from the prior year.
• Receivables was $158.4 million for Q4 2025 at Adma Biologics, up from $137.7 million in the prior quarter.
• Across five years, Receivables topped out at $158.4 million in Q4 2025 and bottomed at $15.4 million in Q1 2021.
• A 5-year average of $48.8 million and a median of $29.3 million in 2021 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables plunged 45.74% — and 2025, when it jumped 264.54%.
• Adma Biologics' Receivables stood at $28.6 million in 2021, then plunged by 45.74% to $15.5 million in 2022, then jumped by 76.85% to $27.4 million in 2023, then surged by 82.34% to $50.0 million in 2024, then surged by 216.86% to $158.4 million in 2025.
• Business Quant data shows ADMA's Receivables at $158.4 million in Q4 2025, $137.7 million in Q3 2025, and $109.7 million in Q2 2025.